Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.45 |
| ▸ | PDE2A | O00408 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.42 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.42 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16573481 | 0.91 | HSP90B1 (0.48) | ADORA2AADORA3ADORA1PDE2AADRA1A | |
| SCHEMBL25394467 | 0.90 | NT5E (0.55) | ADORA2AADORA3ADORA1PDE2AADRA1A | |
| SCHEMBL31652875 | 0.89 | ADORA3 (0.59) | ADORA2AADORA3ADORA1PDE2AADRA1A | |
| SCHEMBL20724560 | 0.86 | ADORA3 (0.44) | ADORA2AADORA3ADORA1NT5EADORA2B | |
| SCHEMBL31652878 | 0.85 | ADORA3 (0.52) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL15070706 | 0.85 | ADORA3 (0.52) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL15964781 | 0.85 | ADORA2A (0.49) | ADORA2AADORA3ADORA1PDE2AADRA1A | |
| SCHEMBL15964785 | 0.82 | ADORA2A (0.45) | ADORA2AADORA3ADORA1PDE2AADRA1A | |
| SCHEMBL15964778 | 0.82 | ADORA2A (0.44) | ADORA2AADORA3ADORA1PDE2AADRA1A | |
| SCHEMBL15964776 | 0.82 | ADORA2A (0.44) | ADORA2AADORA3ADORA1PDE2AADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296777-B2 | 2′,4′-substituted nucleosides as antiviral agents | GILEAD PHARMASSET LLC (US) | 2016-03-29 | — | — | US | disclosed |
| US-20140235563-A1 | 2',4'-SUBSTITUTED NUCLEOSIDES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2014-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235563-A1 | 2',4'-SUBSTITUTED NUCLEOSIDES AS ANTIVIRAL AGENTS | HAVCR2, NUDT1, NT5C3B | ADORA2A 88/4885ADORA3 102/4885ADORA1 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.